Invex\u8fd8\u7ee7\u7eed\u4e0e\u80fd\u591f\u751f\u4ea7Presendin\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u5927\u89c4\u6a21\u5546\u4e1a\u4f9b\u5e94\u7684\u5408\u540c\u751f\u4ea7\u7ec4\u7ec7\u8fdb\u884c\u8ba8\u8bba<\/a>\u3002<\/p>\n\u8be5\u516c\u53f8\u8868\u793a\uff0c\u8003\u8651\u5230\u60a3\u8005\u9700\u8981\u957f\u671f\u4f7f\u7528Presendin\u6765\u7ef4\u6301\u6b63\u5e38\u7684\u9885\u5185\u538b\u6c34\u5e73\uff0c\u5e76\u51cf\u8f7b\u5934\u75db\u548c\u89c6\u529b\u969c\u788d\u7684\u4e34\u5e8a\u75c7\u72b6\uff0c\u5b83\u6709\u4fe1\u5fc3\u53d6\u5f97\u5bf9\u53cc\u65b9\u90fd\u6709\u5229\u7684\u5546\u4e1a\u6210\u679c\u3002<\/p>\n
\u77e5\u8bc6\u4ea7\u6743<\/h2>\n
\u4eca\u5e744\u6708\uff0cInvex\u7684\u77e5\u8bc6\u4ea7\u6743\u8d44\u4ea7\u6709\u6240\u6269\u5f20\uff0cPresendin\u7684\u5546\u6807\u5df2\u4e8e4\u6708\u6b63\u5f0f\u83b7\u5f97\u7f8e\u56fd\u4e13\u5229\u5546\u6807\u5c40(US Patent and Trademark Office)\u7684\u6ce8\u518c\u3002<\/p>\n
\u6b27\u76df\u77e5\u8bc6\u4ea7\u6743\u5c40\u548c\u6fb3\u5927\u5229\u4e9a\u77e5\u8bc6\u4ea7\u6743\u5c40\u8fd8\u6279\u51c6\u4e86\u5176\u4ed6\u6ce8\u518c\u3002<\/p>\n
\u5f3a\u52b2\u7684\u8d22\u52a1\u72b6\u51b5<\/h2>\n
\u672c\u5b63\u5ea6\u672b\uff0cInvex\u8d22\u52a1\u72b6\u51b5\u826f\u597d\uff0c\u73b0\u91d1\u548c\u73b0\u91d1\u7b49\u4ef7\u7269\u4e3a3,270\u4e07\u6fb3\u5143\uff0c\u8fd0\u8425\u652f\u51fa\u7684\u73b0\u91d1\u6d41\u51fa\u603b\u989d\u4e3a45\u4e07\u6fb3\u5143\u3002<\/p>\n
\u73b0\u91d1\u6d41\u51fa\u5305\u62ec17\u4e07\u6fb3\u5143\u7684\u7814\u53d1\u6210\u672c\uff0c\u7528\u4e8e\u51c6\u5907\u548c\u5411\u7f8e\u56fdFDA\u63d0\u4ea4\u7814\u7a76\u65b9\u6848\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\uff0c\u4ee5\u53ca\u4e0e\u4e66\u9762\u56de\u5e94\u76f8\u5173\u7684\u76d1\u7ba1\u5efa\u8bae\u3002<\/p>\n
\u8be5\u516c\u53f8\u8fd8\u53d1\u751f\u4e86\u4e0e\u76f4\u63a5\u7814\u53d1\u76f8\u5173\u7684\u5458\u5de5\u6210\u672c10\u4e07\u6fb3\u5143\u3002<\/p>\n
\u7ba1\u7406\u548c\u516c\u53f8\u652f\u51fa20\u4e07\u6fb3\u5143\uff0c\u4e0easx\u4e0a\u5e02\u516c\u53f8\u7684\u5408\u89c4\u6210\u672c\u6709\u5173\uff0c\u5305\u62ec\u80a1\u7968\u4ea4\u6613\u548c\u8463\u4e8b\u8d39\u7528\uff0c\u4ee5\u53ca\u5ba1\u8ba1\u548c\u6cd5\u5f8b\u8d39\u7528\u3002<\/p>\n
\u5305\u62ec\u4e0a\u8ff0\u6210\u672c\u5728\u5185\uff0c\u672c\u5b63\u5ea6\u652f\u4ed8\u7ed9Invex\u5173\u8054\u65b9\u53ca\u5176\u5173\u8054\u65b9\u7684\u603b\u91d1\u989d\u4e3a17\u4e07\u6fb3\u5143\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002 \u4eca\u5e746\u6708\uff0c\u8be5\u516c\u53f8\u6536\u5230\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(fda)\u795e\u7ecf\u75c5\u5b66\u90e8\u95e8\u5173\u4e8e\u8be5\u836f\u62df\u8bae\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u4e66\u9762\u56de\u590d\u3002 \u54cd\u5e94\u6db5\u76d6\u4e86\u603b\u4f53\u7814\u7a76\u8bbe\u8ba1\uff0c\u7279\u522b\u662f\u5c06\u9885\u5185\u538b\u548c\u5934\u75db\u4f5c\u4e3a\u5173\u952e\u7ec8\u70b9\uff0c\u8fd9\u7b26\u5408\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40(EMA)\u7684\u8981\u6c42\uff0c\u5373\u8bc1\u660e\u9885\u5185\u538b\u548c\u4e34\u5e8a\u7ed3\u679c\u7684\u201c\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\u548c\u4e34\u5e8a\u610f\u4e49\u7684\u5f71\u54cd\u201d\u3002 FDA\u8ba4\u4e3a\u9885\u5185\u538b\u662f\u4e00\u4e2a\u5408\u9002\u7684\u6b21\u8981\u7ec8\u70b9;\u7136\u800c\uff0c\u5efa\u8baeInvex\u8003\u8651\u5bf9\u89c6\u89c9\u529f\u80fd\u6709\u4e34\u5e8a\u610f\u4e49\u7684\u5f71\u54cd\uff0c\u5982\u5468\u56f4\u5e73\u5747\u504f\u5dee(PMD)\u4f5c\u4e3a\u4e3b\u8981\u7ec8\u70b9\u3002 \u6b64\u540e\uff0cInvex\u5df2\u5f00\u59cb\u4e0e\u76d1\u7ba1\u90e8\u95e8\u548c\u79d1\u5b66\u987e\u95ee\u8fdb\u884c\u8ba8\u8bba\uff0c\u4ee5\u8fdb\u4e00\u6b65\u4e86\u89e3\u53cd\u5e94\u548c\u4e34\u5e8a\u7b56\u7565\uff0c\u4ee5\u4fbf\u8bbe\u8ba1\u9002\u7528\u4e8e\u7f8e\u56fdFDA\u548cEMA\u7684III\u671f\u8bd5\u9a8c\u3002 \u5546\u4e1a\u4f9b\u5e94 \u5728\u672c\u5b63\u5ea6\uff0cInvex\u8fd8\u7ee7\u7eed\u4e0e\u80fd\u591f\u751f\u4ea7Presendin\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u5927\u89c4\u6a21\u5546\u4e1a\u4f9b\u5e94\u7684\u5408\u540c\u751f\u4ea7\u7ec4\u7ec7\u8fdb\u884c\u8ba8\u8bba\u3002 \u8be5\u516c\u53f8\u8868\u793a\uff0c\u8003\u8651\u5230\u60a3\u8005\u9700\u8981\u957f\u671f\u4f7f\u7528Presendin\u6765\u7ef4\u6301\u6b63\u5e38\u7684\u9885\u5185\u538b\u6c34\u5e73\uff0c\u5e76\u51cf\u8f7b\u5934\u75db\u548c\u89c6\u529b\u969c\u788d\u7684\u4e34\u5e8a\u75c7\u72b6\uff0c\u5b83\u6709\u4fe1\u5fc3\u53d6\u5f97\u5bf9\u53cc\u65b9\u90fd\u6709\u5229\u7684\u5546\u4e1a\u6210\u679c\u3002 \u77e5\u8bc6\u4ea7\u6743 \u4eca\u5e744\u6708\uff0cInvex\u7684\u77e5\u8bc6\u4ea7\u6743\u8d44\u4ea7\u6709\u6240\u6269\u5f20\uff0cPresendin\u7684\u5546\u6807\u5df2\u4e8e4\u6708\u6b63\u5f0f\u83b7\u5f97\u7f8e\u56fd\u4e13\u5229\u5546\u6807\u5c40(US Patent and Trademark Office)\u7684\u6ce8\u518c\u3002 \u6b27\u76df\u77e5\u8bc6\u4ea7\u6743\u5c40\u548c\u6fb3\u5927\u5229\u4e9a\u77e5\u8bc6\u4ea7\u6743\u5c40\u8fd8\u6279\u51c6\u4e86\u5176\u4ed6\u6ce8\u518c\u3002 \u5f3a\u52b2\u7684\u8d22\u52a1\u72b6\u51b5 \u672c\u5b63\u5ea6\u672b\uff0cInvex\u8d22\u52a1\u72b6\u51b5\u826f\u597d\uff0c\u73b0\u91d1\u548c\u73b0\u91d1\u7b49\u4ef7\u7269\u4e3a3,270\u4e07\u6fb3\u5143\uff0c\u8fd0\u8425\u652f\u51fa\u7684\u73b0\u91d1\u6d41\u51fa\u603b\u989d\u4e3a45\u4e07\u6fb3\u5143\u3002 \u73b0\u91d1\u6d41\u51fa\u5305\u62ec17\u4e07\u6fb3\u5143\u7684\u7814\u53d1\u6210\u672c\uff0c\u7528\u4e8e\u51c6\u5907\u548c\u5411\u7f8e\u56fdFDA\u63d0\u4ea4\u7814\u7a76\u65b9\u6848\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\uff0c\u4ee5\u53ca\u4e0e\u4e66\u9762\u56de\u5e94\u76f8\u5173\u7684\u76d1\u7ba1\u5efa\u8bae\u3002 \u8be5\u516c\u53f8\u8fd8\u53d1\u751f\u4e86\u4e0e\u76f4\u63a5\u7814\u53d1\u76f8\u5173\u7684\u5458\u5de5\u6210\u672c10\u4e07\u6fb3\u5143\u3002 \u7ba1\u7406\u548c\u516c\u53f8\u652f\u51fa20\u4e07\u6fb3\u5143\uff0c\u4e0easx\u4e0a\u5e02\u516c\u53f8\u7684\u5408\u89c4\u6210\u672c\u6709\u5173\uff0c\u5305\u62ec\u80a1\u7968\u4ea4\u6613\u548c\u8463\u4e8b\u8d39\u7528\uff0c\u4ee5\u53ca\u5ba1\u8ba1\u548c\u6cd5\u5f8b\u8d39\u7528\u3002 \u5305\u62ec\u4e0a\u8ff0\u6210\u672c\u5728\u5185\uff0c\u672c\u5b63\u5ea6\u652f\u4ed8\u7ed9Invex\u5173\u8054\u65b9\u53ca\u5176\u5173\u8054\u65b9\u7684\u603b\u91d1\u989d\u4e3a17\u4e07\u6fb3\u5143\u3002<\/p>\n","protected":false},"author":4,"featured_media":12531,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\n
Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76<\/title>\n<meta name=\"description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76\" \/>\n<meta property=\"og:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-25T23:08:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:50:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-2021-quarter-development-Presendin-idiopathic-intracranial-hypertension.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76\" \/>\n<meta name=\"twitter:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/\",\"name\":\"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2021-07-25T23:08:07+00:00\",\"dateModified\":\"2023-08-29T17:50:24+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76","description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76","og_description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/","og_site_name":"smallcapsCN","article_published_time":"2021-07-25T23:08:07+00:00","article_modified_time":"2023-08-29T17:50:24+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-2021-quarter-development-Presendin-idiopathic-intracranial-hypertension.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_title":"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76","twitter_description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/","name":"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2021-07-25T23:08:07+00:00","dateModified":"2023-08-29T17:50:24+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u4e86\u4e00\u4e2a\u7e41\u5fd9\u7684\u5b63\u5ea6\uff0c\u91cd\u70b9\u662fPresendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\uff0c\u7528\u4e8e\u4e0e\u9885\u5185\u538b\u5347\u9ad8(\u4e5f\u79f0\u4e3a\u7279\u53d1\u6027\u9885\u5185\u538b\u5347\u9ad8)\u76f8\u5173\u7684\u795e\u7ecf\u75be\u75c5\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-busy-quarter-presendin-idiopathic-intracranial-hypertension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics\u7ed3\u675f\u4e86Presendin\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u7684\u7814\u7a76"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3519"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3519"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3519\/revisions"}],"predecessor-version":[{"id":12530,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/3519\/revisions\/12530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/12531"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}